Emerging lipid-lowering drugs: squalene synthase inhibitors

Author： Elsayed Raghda K   Evans Jeffery D  

Publisher： Informa Healthcare

ISSN： 1472-8214

Source： Expert Opinion on Emerging Drugs, Vol.13, Iss.2, 2008-06, pp. : 309-322

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia

By Amano Y.   Nishimoto T.   Tozawa R.-i.   Ishikawa E.   Imura Y.   Sugiyama Y.  

European Journal of Pharmacology, Vol. 466, Iss. 1, 2003-04 ,pp. : 155-161

Elsevier

Access to resources Recommend Favorite

Squalene Synthase Inhibitors: Clinical Pharmacology and Cholesterol-Lowering Potential

By Charlton-Menys Valentine   Durrington Paul N.  

Drugs, Vol. 67, Iss. 1, 2007-01 ,pp. : 11-16

Adis International

Access to resources Recommend Favorite

New prospects for lipid-lowering drugs

By Thompson G.R.   Naoumova R.P.  

Expert Opinion on Investigational Drugs, Vol. 7, Iss. 5, 1998-05 ,pp. : 715-727

Informa Healthcare

Access to resources Recommend Favorite

Update of Recent Reforms in Germany to Enhance the Quality and Efficiency of Prescribing of Proton Pump Inhibitors and Lipid-Lowering Drugs

By Godman Brian   Schwabe Ulrich  

PharmacoEconomics, Vol. 27, Iss. 5, 2009-05 ,pp. : 435-438

Adis International

Access to resources Recommend Favorite

Squalene synthase inhibitors 1998

By Rosenberg S.H.  

Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 5, 1998-05 ,pp. : 521-530

Informa Healthcare

Access to resources Recommend Favorite